Recent Company News

• 07:35 AM ET Apr 13, 2026
  

  Allogene Therapeutics reports interim futility analysis from pivotal ALPHA3 trial of cema-cel in first-line consolidation LBCL ($2.72, 0.00)

• 02:16 PM ET Apr 10, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 12-Apr

• 03:21 PM ET Apr 02, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 5-Apr

• 01:31 PM ET Mar 27, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 29-Mar

• 09:23 AM ET Mar 20, 2026
  

  Transcript Intelligence: Cellectis SA Q4 Earnings Guidance

• 09:23 AM ET Mar 20, 2026
  

  Transcript Intelligence: Cellectis SA Q4 Earnings Themes

• 09:23 AM ET Mar 20, 2026
  

  Transcript Intelligence: Cellectis SA Q4 Earnings Q&A

• 07:32 PM ET Mar 19, 2026
  

  Cellectis SA reports Q4 EPS ($0.26) vs FactSet ($0.20) [6 est, ($0.32)-0.04] (€2.97, 0.00)

• 04:41 PM ET Jan 08, 2026
  

  Cellectis SA issues 2026 strategy; first interim analysis of Phase 2 BALLI-01 trial expected to complete in Q4 (€3.95, 0.00)

• 05:37 PM ET Dec 23, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market